NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Autolus Therapeutics plc (AUTL) Stock Analysis

Autolus Therapeutics plc (AUTL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AUTL

$2.24

−$0.05 (−2.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AUTL with… →

AUTL Key Statistics

As of Sep 4, 2026
Trading
Open
$2.31
Previous Close
$2.29
Day's Range
2.22–2.31
52-Week Range
1.18–2.58
Volume
1.83M
Valuation
Market Cap
$596.20M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
552.81
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.03
Financials (FY)
Revenue (FY)
$75.39M+644.94%
Net Income (FY)
−$287.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
266.16M
1-Year Return
+54.48%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
1.93M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AUTL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.56%
2025−15.32%
2024−63.51%
2023+238.95%
2022−63.39%
2021−41.95%
2020−32.27%
2019−59.81%
2018 (partial year)+31.36%

As of September 4, 2026.

AUTL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$75.39M−$287.53M−381.4%
2024$10.12M−$220.66M−2180.5%
2023$1.70M−$208.38M−12272.3%
2022$6.19M−$148.84M−2403.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$75.39M−$20.98M−$270.54M−$287.53M−381.4%
2024$10.12M−$1.27M−$241.43M−$220.66M−2180.5%
2023$1.70M$1.70M−$175.53M−$208.38M−12272.3%
2022$6.19M—−$142.89M−$148.84M−2403.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AUTL Valuation vs Biotechnology Median

Median of 656 stocks
MetricAUTLBiotechnology medianvs median
P/S ratio552.8115.2636.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Autolus Therapeutics plc (AUTL) at $596.20M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 752.

Over the past 52 weeks the price has ranged from $1.18 to $2.58. The most recent close on file for AUTL is $2.24, dated September 4, 2026. That is −$0.05 (−2.18%) against the previous close. The latest close sits 90.64% above that 52-week low.

Financial Health

In fiscal 2025, Autolus Therapeutics plc reported revenue of $75.39M. Against the prior fiscal year total of $10.12M, that is a change of +644.94%. The same year closed with a net loss of $287.53M. Profit margin runs at 0%. Trailing earnings per share are −1.03.

Across the 4 fiscal years on file, revenue moves from $6.19M in 2022 to $75.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 552.81 times revenue. On price-to-sales that is 36.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Daily returns over the trailing 8 years annualize to a volatility of 81.2%. The trailing one-year price return is +54.48%. Across 5 years the annualized return works out at −20.98%.

Growth & Income

No dividend is on file for AUTL.

So far in 2026 the price is +12.56%. The strongest complete calendar year on file is 2023 at +238.95%; the weakest is 2024 at −63.51%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

Autolus Therapeutics plc (AUTL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Autolus Therapeutics plc AUTL $596.20M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Autolus Therapeutics plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Visit website →